Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Clovis Oncology Stock Jumps as FDA Skips Review Panel for New Cancer Drug

Clovis Oncology shares jumped more than 15 percent after the FDA opted to not hold an advisory committee meeting to discuss the company’s application for its ovarian cancer drug rucaparib.

Read More »

Retrophin kidney drug succeeds in mid-stage study, shares jump

Retrophin Inc. said its drug to treat a rare kidney disorder was found effective in a mid-stage study.

Read More »

Tonix to stop testing drug for fibromyalgia

Tonix Pharmaceuticals Holding Corp. said it would stop developing its drug for fibromyalgia after the treatment failed in a late-stage trial.

Read More »

Novo Nordisk’s veteran CEO to step down

Novo Nordisk’s chief executive Lars Rebien Sorensen is to step down at a time when the world’s largest insulin maker has said it faces increased U.S. competition.

Read More »

Rigel’s bleeding disorder drug clears key trial

Rigel Pharmaceuticals Inc. said its experimental drug to treat a bleeding disorder met its main goal in the first of two late-stage trials.

Read More »

Lung disease therapy misses primary trial goal

Drugmaker Vectura Group Plc said its asthma therapy Flutiform had not met the primary endpoint in a late-stage trial to determine its ability to treat COPD.

Read More »

Valeant is sued over Philidor ties, alleged racketeering

Valeant Pharmaceuticals International Inc. was sued by buyers of its drugs, who accused the Canadian company of racketeering by forcing them to pay exorbitant prices.

Read More »

Pfizer to buy AstraZeneca’s antibiotics business

Pharmaceutical company AstraZeneca has agreed to sell its small molecule antibiotics business to Pfizer Inc. in a deal that could be valued at more than $1.5 billion.

Read More »

Pfizer Acquires Medivation for $14 Billion

Pfizer Inc. – beating out numerous other bidders – said it would buy U.S. cancer drug company Medivation Inc. for $14 billion in cash.

Read More »

FDA widens use of Edwards’ devices for heart valve replacement

The U.S. Food and Drug Administration has widened the use of Edwards Lifesciences’ heart valves to patients at intermediate risk of complications if they underwent open heart surgery.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom